Board Member
Outlook Therapeutics, Inc. (OTLK)Equibles does not estimate personal net worth.
Get an email with a short summary when Outlook Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get OTLK alertsLawrence A. Kenyon is recorded as Board Member at Outlook Therapeutics, Inc. (OTLK) since January 30, 2025. Outlook Therapeutics, Inc. reported in an 8-K filed August 27, 2026 that Lawrence A. Kenyon resigned as member of the Board of Directors. Outlook Therapeutics, Inc. reported in an 8-K filed January 31, 2025 that Lawrence A. Kenyon was appointed Class III director, effective January 30, 2025. Outlook Therapeutics, Inc. reported in an 8-K filed January 31, 2025 that Lawrence A. Kenyon resigned as Class II director, effective January 30, 2025. Equibles holds 4 filed executive changes naming Lawrence A. Kenyon; each is listed under recent activity with its source filing. The proxy statement of Outlook Therapeutics, Inc. reports total compensation of $476,170 for Lawrence A. Kenyon in fiscal 2025, including a base salary of $475,000. Disclosed compensation is on record for 6 fiscal years. Lawrence A. Kenyon has spoken on 1 earnings call across 1 company, most recently for Outlook Therapeutics, Inc. on August 14, 2026. Outlook Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Outlook Therapeutics, Inc. includes Robert C. Jahr (CEO and Board Member), Robert Charles Jahr (CEO and Board Member), Faisal G. Sukhtian (Chairman) and 7 others.
“your resignation, effective on or before the Planned Separation Date as a member of the Board of Directors”
“effective January 30, 2025, Mr. Kenyon resigned as a Class II director and was immediately elected by the Board as a Class III director, effective as of January 30, 2025.”
“For the third quarter of fiscal 2026, we reported adjusted net loss attributable to common stockholders of $10.9 million or $0.09 per basic and diluted share compared with $15.8 million or $0.44 per basic and diluted share in the third quarter of fiscal 2025.”
2025-01-30–present
2025-01-30–2026-08-27
2024-12-03–2025-02-10
Last confirmed by a filing; no departure on record
Start not stated–2025-01-30
Start not stated–2026-09-01
Biotechnology · Healthcare
Board Member
2024-12-03–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Outlook Therapeutics, Inc. (OTLK) | Executive Vice President and Chief Financial Officer; Former Interim Chief Executive Officer | $475,000 | $476,170 |
| 2024 | Outlook Therapeutics, Inc. (OTLK) | Executive Vice President and Chief Financial Officer; Former Interim Chief Executive Officer | $475,000 | $634,597 |
| 2021 | Outlook Therapeutics, Inc. (OTLK) | Executive Vice President, Chief Financial Officer, Treasurer and Corporate Secretary | $425,000 | $2,669,214 |
| 2020 | Outlook Therapeutics, Inc. (OTLK) | Executive Vice President, Chief Financial Officer, Treasurer and Corporate Secretary | $425,000 | $1,184,334 |
| 2019 | Outlook Therapeutics, Inc. (OTLK) | Director, Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary | $425,000 | $1,863,901 |
| 2018 | Outlook Therapeutics, Inc. (OTLK) | Director, Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary | $371,635 | $716,132 |
